Fullcircle Wealth LLC acquired a new stake in Stryker Co. (NYSE:SYK - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 669 shares of the medical technology company's stock, valued at approximately $260,000.
Several other institutional investors and hedge funds have also modified their holdings of the business. Kohmann Bosshard Financial Services LLC acquired a new position in Stryker during the 4th quarter worth $25,000. Rakuten Securities Inc. lifted its position in Stryker by 618.2% during the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock worth $28,000 after acquiring an additional 68 shares during the last quarter. Centricity Wealth Management LLC acquired a new position in Stryker during the 4th quarter worth $30,000. BankPlus Trust Department acquired a new position in Stryker during the 4th quarter worth $33,000. Finally, Activest Wealth Management acquired a new position in Stryker during the 4th quarter worth $36,000. Institutional investors and hedge funds own 77.09% of the company's stock.
Analyst Upgrades and Downgrades
A number of research firms have weighed in on SYK. Citigroup reissued a "buy" rating and set a $450.00 target price on shares of Stryker in a research report on Wednesday, February 26th. Argus set a $450.00 price objective on shares of Stryker in a research report on Monday, February 3rd. StockNews.com lowered shares of Stryker from a "buy" rating to a "hold" rating in a research report on Thursday, March 6th. BTIG Research set a $403.00 price objective on shares of Stryker and gave the company a "buy" rating in a research report on Monday, April 14th. Finally, Evercore ISI cut their price objective on shares of Stryker from $400.00 to $390.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. Based on data from MarketBeat, Stryker presently has a consensus rating of "Moderate Buy" and an average target price of $427.05.
Read Our Latest Stock Analysis on SYK
Insider Buying and Selling at Stryker
In other news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now directly owns 14,895 shares of the company's stock, valued at $5,705,827.65. This trade represents a 14.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the transaction, the director now directly owns 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. This represents a 5.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company's stock.
Stryker Price Performance
Shares of SYK traded down $1.59 during mid-day trading on Friday, hitting $380.87. 758,784 shares of the company traded hands, compared to its average volume of 1,356,009. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The business has a 50-day moving average of $365.47 and a 200 day moving average of $374.48. The stock has a market capitalization of $145.37 billion, a price-to-earnings ratio of 49.08, a PEG ratio of 2.93 and a beta of 0.93.
Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, beating the consensus estimate of $2.73 by $0.11. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The business had revenue of $5.87 billion for the quarter, compared to analysts' expectations of $5.68 billion. During the same period in the prior year, the firm earned $2.50 earnings per share. Stryker's revenue was up 11.9% compared to the same quarter last year. As a group, equities analysts expect that Stryker Co. will post 13.47 earnings per share for the current fiscal year.
Stryker Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be paid a $0.84 dividend. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. Stryker's payout ratio is presently 45.41%.
About Stryker
(
Free Report)
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
Further Reading
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
